Altimmune HepTcell Abstract for Presentation at BSI/NVVI Congress 2016

[sorte]

December 06, 2016 09:50 ET | Source: Altimmune, Inc.
GAITHERSBURG, Md., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that its abstract related to the development of an assay to detect low frequency antigen-specific T cells in HepTcell trial participants was accepted for presentation at the BSI/NVVI Congress 2016 taking place December 6 - 9, 2016 in Liverpool, U.K. HepTcell is Altimmune’s first-in-class T cell-activating immunotherapeutic in development for the treatment of chronic hepatitis B (CHB). A Phase 1 trial is currently underway.

The BSI/NVVI Congress 2016 is a joint collaboration between the British Society for Immunology (BSI) and the Dutch Society for Immunology (NVVI), two of Europe’s most established immunology organizations, to bring together the latest in cutting-edge immunology research.

The poster, entitled, “Development of a cultured ELISpot assay to detect low frequency antigen-specific T cells in PBMC from HBV therapeutic vaccine trial participants," will be presented by V. Motskin on Thursday, December 8, 2016 from 5:30 – 7:30 PM GMT.
https://globenewswire.com/news-release/2016/12/06/895510/0/en/UPDATE-Altimmune-Announces-Acceptance-of-HepTcell-Abstract-for-Presentation-at-BSI-NVVI-Congress-2016.html

[sorte]

I think early results from their clinical trial would be more interesting :/

[sorte]

https://clinicaltrials.gov/ct2/show/NCT02496897?term=Altimmune&rank=1